Capricor Therapeutics’ investigational therapy deramiocel (CAP-1002) is being considered for approval in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback